CXCR3 enhanced murine chimeric antigen receptor T cells in the treatment of solid tumors.

ABSTRACT:

Background

Chimeric antigen receptor T cell (CAR-T) therapy has achieved remarkable success in the treatment of hematologic malignancies, but its efficacy against solid tumors remains limited. This limitation primarily arises from the physical and molecular barriers that restrict CAR-T infiltration. The CXCL10-CXCR3 axis plays a critical role in mediating immune cell migration. Notably, elevated CXCR3 expression in solid tumors is correlated with improved immune infiltration and patient survival. Furthermore, the downregulation of CXCR3 in CD8⁺ T cells was observed in tumor microenvironments, limiting their ability to infiltrate tumors. Therefore, we hypothesize that CXCR3-modified CAR-T will exhibit enhanced tumor infiltration capacity, thereby improving the therapeutic

SUBMITTER: Zhang X 

PROVIDER: S-EPMC12605603 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature